Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBT Margin (2018 - 2025)

Serina Therapeutics (SER) has disclosed EBT Margin for 8 consecutive years, with 4287.69% as the latest value for Q2 2025.

  • Quarterly EBT Margin rose 389466.0% to 4287.69% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 18642.31% through Dec 2025, up 1273984.0% year-over-year, with the annual reading at 14766.92% for FY2025, 524558.0% up from the prior year.
  • EBT Margin hit 4287.69% in Q2 2025 for Serina Therapeutics, down from 39757.14% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 39757.14% in Q4 2024 to a low of 54140.0% in Q1 2022.
  • Historically, EBT Margin has averaged 14654.64% across 5 years, with a median of 8182.35% in 2024.
  • Biggest five-year swings in EBT Margin: crashed -5058107bps in 2022 and later skyrocketed 5064667bps in 2023.
  • Year by year, EBT Margin stood at 8377.78% in 2021, then tumbled by -312bps to 34500.0% in 2022, then soared by 100bps to 2.11% in 2023, then surged by 1888058bps to 39757.14% in 2024, then plummeted by -111bps to 4287.69% in 2025.
  • Business Quant data shows EBT Margin for SER at 4287.69% in Q2 2025, 39757.14% in Q4 2024, and 38057.14% in Q3 2024.